Lupin Turns Up Heat With Bausch Brands Acquisition, Perforomist Generic Launch
Generic Spiriva Launch Awaited, Seeks Xopenex Gains
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise
You may also be interested in...
Lupin has revealed details of the German launch of its Luforbec (beclometasone/formoterol) branded generic rival to Foster through its local Hormosan subsidiary, as part of the Indian firm’s wider push in the respiratory category.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.